S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Laser breakthrough could send stock soaring 2,467% (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
Laser breakthrough could send stock soaring 2,467% (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: World stocks mixed as Wall St inches toward bull market
NASDAQ:MBIO

Mustang Bio (MBIO) Competitors

$6.11
+0.03 (+0.49%)
(As of 06/6/2023 ET)
Compare
Today's Range
$5.98
$6.31
50-Day Range
$2.82
$6.39
52-Week Range
$2.82
$14.10
Volume
32,318 shs
Average Volume
53,406 shs
Market Capitalization
$49.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.33

MBIO vs. GNPX, MEIP, UBX, NXTC, BYSI, SLS, ENLV, NBRV, ENOB, and RAIN

Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Genprex (GNPX), MEI Pharma (MEIP), Unity Biotechnology (UBX), NextCure (NXTC), BeyondSpring (BYSI), SELLAS Life Sciences Group (SLS), Enlivex Therapeutics (ENLV), Nabriva Therapeutics (NBRV), Enochian Biosciences (ENOB), and Rain Oncology (RAIN). These companies are all part of the "pharmaceutical preparations" industry.

Mustang Bio vs.

Mustang Bio (NASDAQ:MBIO) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Genprex's return on equity of -109.81% beat Mustang Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang Bio N/A -133.84% -75.03%
Genprex N/A -109.81% -97.89%

Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.33, suggesting that its stock price is 133% less volatile than the S&P 500.

13.7% of Mustang Bio shares are held by institutional investors. Comparatively, 9.1% of Genprex shares are held by institutional investors. 2.1% of Mustang Bio shares are held by company insiders. Comparatively, 12.0% of Genprex shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genprex received 30 more outperform votes than Mustang Bio when rated by MarketBeat users. Likewise, 64.90% of users gave Genprex an outperform vote while only 64.34% of users gave Mustang Bio an outperform vote.

CompanyUnderperformOutperform
Mustang BioOutperform Votes
166
64.34%
Underperform Votes
92
35.66%
GenprexOutperform Votes
196
64.90%
Underperform Votes
106
35.10%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$77.53 million-$10.31-0.59
GenprexN/AN/A-$23.74 millionN/AN/A

In the previous week, Genprex had 6 more articles in the media than Mustang Bio. MarketBeat recorded 7 mentions for Genprex and 1 mentions for Mustang Bio. Genprex's average media sentiment score of 0.86 beat Mustang Bio's score of 0.00 indicating that Genprex is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mustang Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Genprex
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Mustang Bio currently has a consensus price target of $43.33, suggesting a potential upside of 609.22%. Genprex has a consensus price target of $3.00, suggesting a potential upside of 212.50%. Given Mustang Bio's higher probable upside, analysts clearly believe Mustang Bio is more favorable than Genprex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Genprex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Genprex beats Mustang Bio on 7 of the 12 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBIO vs. The Competition

MetricMustang BioPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$49.86M$6.03B$4.54B$6.29B
Dividend YieldN/A2.62%5.90%6.51%
P/E Ratio-0.595.0188.2812.32
Price / SalesN/A329.063,506.8596.71
Price / CashN/A20.4722.5223.57
Price / Book0.954.894.735.39
Net Income-$77.53M$197.59M$116.85M$192.53M
7 Day Performance-1.61%4.49%4.68%3.72%
1 Month Performance44.79%1.79%2.51%5.12%
1 Year Performance-30.96%22.82%15.61%2.97%

Mustang Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNPX
Genprex
2.7211 of 5 stars
$0.96
+1.1%
$3.00
+212.5%
-34.2%$49.90MN/A0.0012Gap Down
MEIP
MEI Pharma
2.2283 of 5 stars
$7.44
+0.3%
$40.00
+437.6%
-31.1%$49.55M$40.70M-1.3576
UBX
Unity Biotechnology
2.2522 of 5 stars
$3.50
+4.8%
$6.75
+92.9%
-50.4%$50.26M$240,000.00-0.7065
NXTC
NextCure
2.1329 of 5 stars
$1.82
+3.4%
$7.00
+284.6%
-58.1%$50.65M$22.38M-0.7287Gap Up
BYSI
BeyondSpring
0 of 5 stars
$1.25
-8.8%
$1.25
-20.9%$48.65M$1.35M0.0091Gap Up
SLS
SELLAS Life Sciences Group
1.6876 of 5 stars
$1.70
-0.6%
$7.00
+311.8%
-41.6%$48.20M$1M-1.037Gap Up
ENLV
Enlivex Therapeutics
2.0432 of 5 stars
$2.59
-2.3%
$15.00
+479.2%
-49.5%$48.10MN/A-1.5350Upcoming Earnings
News Coverage
High Trading Volume
NBRV
Nabriva Therapeutics
0 of 5 stars
$1.46
-2.7%
N/A-70.8%$46.74M$36.94M-0.0872Gap Down
ENOB
Enochian Biosciences
0 of 5 stars
$0.79
+8.2%
N/A-75.6%$45.94MN/A-0.9611Positive News
RAIN
Rain Oncology
2.7811 of 5 stars
$1.25
flat
$17.00
+1,260.0%
-50.0%$45.45MN/A-0.4844Analyst Downgrade

Related Companies and Tools

This page (NASDAQ:MBIO) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -